Bionano Genomics Announces Global User Event at Bionano Laboratories Before American Society of Human Genetics (ASHG) Annual Meeting
The day’s programming will include a tour of the state-of-the-art Bionano Laboratories, with a hands-on demonstration of the OGM workflow by experienced technologists. Expert Bionano scientists and renowned researchers, including
“Our user meeting is a terrific opportunity to showcase
“Bionano is excited to host its first ‘Meet the User’ event, which will bring together scientific leaders who have pioneered use of OGM and researchers who want to learn more about how our OGM technology can improve their research work unraveling the genomic aberrations associated with a genetic disease. The response to this event has been tremendous, with over fifty attendees traveling from countries across the world. We look forward to in-depth case presentations, demonstrations of the Saphyr system at our new CLIA-certified lab, and the opportunity for researchers to learn from each other,” commented Erik Holmlin, president and chief executive officer of Bionano.
About
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “can” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the utility of OGM to help researchers unravel genomic aberrations associated with genetic diseases. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure OGM to achieve utility in helping to unravel genomic aberrations associated with genetic diseases; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
+1 (858) 366-3243
amy@juniper-point.com
Source: Bionano Genomics